Abstract: A method for treating coronavirus infection by administering to a subject in need of the treatment an effective amount of one or more of the following compounds: aklavin, sanguinarine, amiodarone, chlorpromazine, clomiphene, dihydroergotamine, dipyridamole, emetine, ephedrine, prochlorperazine, promazine, propiomazine, aminacrine, fluphenazine, fenoterol, peruvoside, proglumide, atenolol, nerifolin, nefopam, cycloheximide, avermectin B1, bepridil, cinnarizine, ethisterone, pararosaniline, methylbenzethonium, niclosamide, pipobroman, homidium, calcimycin, anisomycin, metergoline, amodiaquine, danazol, danthron, ethopropazine, eucatropine, nortriptyline, resorcinol, mebhydrolin, mebeverine, trimipramine, triflupromazine, chlorprothixene, cyclobenzaprine, enoxacin, sulfanitran, monensin, nigericin, perphenazine, methoxamine, astemizole, trifluoperazine, acriflavinium, rotenone, acebutolol, quabain, methiothepin, convallatoxin, halcinonide, cyclosporin, pimethixene, mycophenolic acid, promethazine, mesoridazine,

Abstract: A method for treating coronavirus infection by administering to a subject in need of the treatment an effective amount of one or more of the following compounds: aklavin, sanguinarine, amiodarone, chlorpromazine, clomiphene, dihydroergotamine, dipyridamole, emetine, ephedrine, prochlorperazine, promazine, propiomazine, aminacrine, fluphenazine, fenoterol, peruvoside, proglumide, atenolol, nerifolin, nefopam, cycloheximide, avermectin B1, bepridil, cinnarizine, ethisterone, pararosaniline, methylbenzethonium, niclosamide, pipobroman, homidium, calcimycin, anisomycin, metergoline, amodiaquine, danazol, danthron, ethopropazine, eucatropine, nortriptyline, resorcinol, mebhydrolin, mebeverine, trimipramine, triflupromazine, chlorprothixene, cyclobenzaprine, enoxacin, sulfanitran, monensin, nigericin, perphenazine, methoxamine, astemizole, trifluoperazine, acriflavinium, rotenone, acebutolol, quabain, methiothepin, convallatoxin, halcinonide, cyclosporin, pimethixene, mycophenolic acid, promethazine, mesoridazine,

Abstract: This invention relates to methods of inhibiting tubulin polymerization and treating cancer and other angiogenesis-related disorders with indole compounds of the formula: wherein L1, L2, R1, R2, Ra, Rb, Rc, Rd, and Re are defined herein.

Abstract: This invention relates to an extract of Chlorella sorokiniana, which contains myristic acid, palmitic acid, palmitoleic acid, oleic acid, linoleic acid, linolenic acid, and stearic acid. Also related is use of this extract to treat diabetes, obesity, and dyslipidaemia.

Abstract: Compounds of the following formula: wherein A, D, Q, T, U, V, W, X, Y, Z, R1, and are as defined herein. This invention also relates to a method of inhibiting tubulin polymerization, or treating cancer or an angiogenesis-related disorder with one of these compounds.

Abstract: This invention relates to treating peroxisome proliferator-activated receptors related diseases with certain indole compounds. The indole compounds are of formula (I) below. Each variable is defined in the specification.

Abstract: A compound of the following formula: wherein R1, R2, R3, R4, R5, R6, R7, R8, T, X, Y, and Z are as defined herein. Also disclosed is a method for inhibiting dipeptidyl peptidase IV or for treating Type II diabetes with such a compound.

Abstract: A series of indoline-sulfonamide compounds is disclosed. The formula of indoline-sulfonamide compounds is shown as formula (I). In formula (I), R1 is H or halogen; R2 is Ar, Ar—C(O)—, Ar—CH2—, Ar—SO2—, Ar—O—C(O), or R?—C(O)—, and Ar is a substituted or unsubstituted C5-C20 aryl, cyclyl, heterocyclyl, or heteroaryl, R? and R? independently is C1-C10 alkyl, or C1-C10 alkoxyl; and R3 is C5-C15 aryl or C1-C10 alkyl. The indoline-sulfonamide compounds disclosed in the present invention are characterized in inhibiting tubulin polymerization, and treating cancers and other tubulin polymerization-related disorders with a suitable pharmaceutical acceptable carrier.

Abstract: A compound of the following formula: wherein R1, R2, R3, R4, R5, R6, R7, R8, T, X, Y, and Z are as defined herein. Also disclosed is a method for inhibiting dipeptidyl peptidase IV or for treating Type II diabetes with such a compound.

Abstract: Compounds of the following formula: wherein A, D, Q, T, U, V, W, X, Y, Z, R1, and ---- are as defined herein. This invention also relates to a method of inhibiting tubulin polymerization, or treating cancer or an angiogenesis-related disorder with one of these compounds.

Abstract: This invention relates to a method for modulating activity of SARS CoV main protease or an analogue thereof by contacting the protein with an effective amount of a compound of the following formula: A1-L-A2 wherein A1, A2, and L are defined herein, and use of the compound in treating coronavirus infection, hepatitis C virus infection, hemophilia, vascular restenosis, or hypertension.

Abstract: This invention relates to methods of inhibiting tubulin polymerization and treating cancer and other angiogenesis-related disorders with indole compounds of the formula: wherein L1, L2, R1, R2, Ra, Rb, Rc, Rd, and Re are defined herein.

Abstract: Indole compounds of the formula: wherein L1, L2, R1, R2, Ra, Rb, Rc, Rd, and Re are defined herein. Also disclosed are methods of using of the indole compounds in inhibiting tubulin polymerization and treating cancer and other angiogenesis-related disorders.

Abstract: A compound of the following formula: wherein R1 R2, R3, R4, R5, R6, W, X, Y, Z, m, n, and p are as defined herein. This invention also covers methods for inhibiting dipeptidyl peptidase IV or VIII, or treating Type II diabetes with such a compound.

Abstract: Indole compounds of the formula: wherein L1 is CO; L2 is a bond; R1 is aryl or heteroaryl; R2 is H, aryl, heteroaryl, halogen, nitro, nitroso, cyano, azide, isothionitro, OR, OC(O)R, OC(O)OR, OC(O)NRR?, SO2R, SO3R, SO2NRR?, SR, NRR?, NRSO2NR?R?, NRSO2R?, NRSO3R?, NRC(O)R?, NRC(O)NR?R?, NRC(O)OR?, NRC(N)NR?R?, C(O)OR, or C(O)NRR?; each of Ra, Rb, Rc, and Rd, independently, is R, halogen, nitro, nitroso, cyano, azide, isothionitro, OR, OC(O)R, OC(O)OR, OC(O)NRR?, SO2R, SO3R, SO2NRR?, SR, NRR?, NRSO2NR?R?, NRSO2R?, NRSO3R?, NRC(O)R?, NRC(O)NR?R?, NRC(O)OR?, NRC(N)NR?R?, C(O)R, C(O)OR, C(O)NRR?, or Rb and Rc, Ra and Rb, or Rc and Rd taken together are O(CH2)nO; and Rc is H, alkyl, alkenyl, alkynyl, cyclyl, heterocyclyl, halogen, nitro, nitroso, cyano, azide, isothionitro, OR, OC(O)R, OC(O)OR, OC(O)NRR?, SO2R, SO3R, SO2NRR?, SR, NRR?, NRSO2NR?R?, NRSO2R?, NRSO3R?, NRC(O)R?, NRC(O)NR?R?, NRC(O)OR?, NRC(N)NR?R?, C(O)R, C(O)OR, or C(O)NRR?; in which each of R, R?, and R?, independently, is H, alkyl, alkenyl, alky

Abstract: This invention relates to treating peroxisome proliferator-activated receptors related diseases with certain indole compounds. The indole compounds are of formula (I) below. Each variable is defined in the specification.

Abstract: This invention relates to a method for treating HCV infection. The method includes administering to a subject in need thereof an effective amount of one or more of sesquiterpene lactones having a &ggr;-lactone fused with a 10-membered ring, an 8-membered ring that is further fused with a 4-membered ring, a 7-membered ring that is further fused with a 5-membered ring, or a 6-membered ring that is further fused with a 6-membered ring.

Abstract: This invention features a method for treating infection by herpesvirus.

Abstract: Indole compounds of the formula: 1

Abstract: New steroidal polyamines have the structure of formula I or formula II: ##STR1## wherein R.sub.1 and R.sub.2 are independently N(R').sub.3.sup.+ or H in the .alpha.- or .beta.- position except both R.sub.1 and R.sub.2 are not H;R.sub.3 is N(R').sub.3.sup.+ in the .alpha.- position or hydrogenR.sub.4 is OH, N(R').sub.3, or NHC(NH.sub.2)NH.sub.2.sup.+R' is hydrogen, alkyl of one to four carbons, aralkyl, or combinations thereof.